Portage biotech highlights first patient dosed in imp-mel study of port-2 for the treatment of melanoma and non-small cell lung cancer (nsclc)

Westport, conn., aug. 05, 2021 (globe newswire) -- portage biotech inc., (nasdaq: prtg) (“portage” or the “company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the first patient has been dosed in the oxford-led imp-mel study, a phase 1/2, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of port-2, a liposome formulation of the invariant natural killer t-cell (inkt) agonist imm60 developed for the treatment of solid tumors.
ATON Ratings Summary
ATON Quant Ranking